A review of biomarkers in the context of type 1 diabetes: Biological sensing for enhanced glucose control

Bioengineering & Translational Medicine

Farshad Tehrani¹  Joseph Wang¹  Hazhir Teymourian¹  Eva Vargas¹  Kelilah L. Wolkowicz²  Eyal Dassau²  Francis J. Doyle III²  Eleonora M. Aiello²  Mary‐Elizabeth Patti³  Lori M. Laffel³  Jordan E. Pinsker⁴ 

[1] Department of Nanoengineering University of California San Diego La Jolla California USA;Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University Cambridge Massachusetts USA;Joslin Diabetes Center, Harvard Medical School Boston Massachusetts USA;Sansum Diabetes Research Institute Santa Barbara California USA;

关键词: automated insulin delivery;    biosensors;    measurement;    medical devices;    nanobiology;    type 1 diabetes;   

DOI  :  10.1002/btm2.10201

来源: DOAJ

【 摘 要 】

Abstract As wearable healthcare monitoring systems advance, there is immense potential for biological sensing to enhance the management of type 1 diabetes (T1D). The aim of this work is to describe the ongoing development of biomarker analytes in the context of T1D. Technological advances in transdermal biosensing offer remarkable opportunities to move from research laboratories to clinical point‐of‐care applications. In this review, a range of analytes, including glucose, insulin, glucagon, cortisol, lactate, epinephrine, and alcohol, as well as ketones such as beta‐hydroxybutyrate, will be evaluated to determine the current status and research direction of those analytes specifically relevant to T1D management, using both in‐vitro and on‐body detection. Understanding state‐of‐the‐art developments in biosensing technologies will aid in bridging the gap from bench‐to‐clinic T1D analyte measurement advancement.

【 授权许可】

Unknown